Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$49.66M+2.1%-$50.71M-0.2%-$50.61M+27.8%-$70.06M-44.4%-$48.5M-1.8%
$79K0.0%$79K0.0%$79K+2.6%$77K+1.3%$76K-1.3%
$7.62M+4.2%$7.31M-22.8%$9.47M-4.2%$9.89M+5.5%$9.37M-2.7%
-$46.05M-20.8%-$38.11M-3.3%-$36.88M+36.0%-$57.61M-33.5%-$43.16M-17.8%
$11K
$32.41M+44.8%$22.39M-66.8%$67.39M+26.2%$53.4M+45.1%$36.81M
$380K-46.9%$715K$0-100%$373K$0-100%
-$13.25M$30.52M+896%-$3.84M+39.6%-$6.35M+66.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Cullinan Therapeutics, Inc. generate?
Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.
What is Cullinan Therapeutics, Inc.'s free cash flow?
After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.
Where does Cullinan Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.